Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

Funding will advance Strand’s pipeline and mission to bring targeted, next-generation mRNA therapies to patients ...